Combination lipid therapy in type 2 diabetes.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. The role of triglyceride in cardiovascular disease in asian patients with type 2 diabetes--a systematic review.The review of diabetic studies : RDS
   Pooled it
2. Pharmacokinetic Comparison Between a Fixed-Dose Combination of Atorvastatin/Fenofibrate 20/145 mg and the Corresponding Individual Components.Clinical pharmacology in drug development · 2026
   Trial
3. Study Design and Protocol for a Randomized Controlled Trial to Assess Long-Term Efficacy and Safety of a Triple Combination of Ezetimibe, Fenofibrate, and Moderate-Intensity Statin in Patients with Type 2 Diabetes and Modifiable Cardiovascular Risk Factors (ENSEMBLE).Endocrinology and metabolism (Seoul, Korea) · 2024
   Article
4. Classical and Novel Lipid-Lowering Therapies for Diabetic Patients with Established Coronary Artery Disease or High Risk of Coronary Artery Disease-A Narrative Clinical Review.Pharmaceuticals (Basel, Switzerland) · 2024
   Review
5. Impact of peroxisome proliferator-activated receptor-α on diabetic cardiomyopathy.Cardiovascular diabetology · 2021
   Review
6. Interactive effects of a common γ-glutamyltransferase 1 variant and low high-density lipoprotein-cholesterol on diabetic macro- and micro-angiopathy.Cardiovascular diabetology · 2015
   Article
7. Observational study to evaluate the safety and efficacy of saroglitazar in Indian diabetic dyslipidemia patients.Indian heart journal
   Observational

Corrections and comments

• Comment on
  Effects of combination lipid therapy in type 2 diabetes mellitus.2010

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as